tak-243
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 3, 2019 (NCT03816319)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
UBA3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NS(=O)(=O)OC[C@H]1C[C@@H](Nc2ccnc3cc(-c4cccc(SC(F)(F)F)c4)nn23)[C@H](O)[C@@H]1O- Mol. weight
- 519.53 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297405 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06223542 | Phase 1 | May 27, 2025 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT03816319 | Phase 1 | Oct 3, 2019 | National Cancer Institute (NCI), University of Toronto |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 2 | 1 | 2019 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2025 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1